Businesses
News releases, reports, statements and associated documents from U.S. and international businesses.
Featured Stories
White & Case Advises IFC-Led Lender Group on $1.25B Financing for Indorama Eleme Fertilizer and Chemicals
NEW YORK, April 17 -- White and Case, a law firm, issued the following news release:
Global law firm White & Case LLP has advised a group of lenders led by the International Finance Corporation (IFC) on a US$1.25 billion financing package to Indorama Eleme Fertilizer and Chemicals Limited (Indorama) in Nigeria.
"This is a transformational deal for the sponsor and reflects the longstanding commitment and relationship between Indorama and the DFIs which have supported it from the first financing in 2013," said White & Case partner Deji Adegoke, who co-led the Firm's deal team. "This landmark deal
... Show Full Article
NEW YORK, April 17 -- White and Case, a law firm, issued the following news release:
Global law firm White & Case LLP has advised a group of lenders led by the International Finance Corporation (IFC) on a US$1.25 billion financing package to Indorama Eleme Fertilizer and Chemicals Limited (Indorama) in Nigeria.
"This is a transformational deal for the sponsor and reflects the longstanding commitment and relationship between Indorama and the DFIs which have supported it from the first financing in 2013," said White & Case partner Deji Adegoke, who co-led the Firm's deal team. "This landmark dealrepresents the high point of PPP-type hybrid financings. Its complex nature as well as the scale of the documentation package was managed in a collaborative and effective manner by our cross-border team."
The financing will provide the required investment for Indorama to build a third nitrogenous urea fertiliser plant, with expected annual capacity of 1.4 million metric tonnes of urea, and a new shipping terminal base in Nigeria. As well as IFC, the group of development finance institutions which provided the financing included African Development Bank, British International Investment Plc, DEG - Deutsche Investitions und Entwicklungsgesellschaft mbH, United States International Development Finance Corporation, The Emerging Africa Infrastructure Fund Limited, The Export-Import Bank of Korea, Export Import Bank of India, Nederlandse Financierings - MaatsChappij Voor Ontwikkelingslanden N.V.
White & Case advised on all aspects of the transaction including project development, due diligence, commercial launch and the negotiation and drafting of finance documents.
Based near Port Harcourt in Nigeria, the Indorama facility is Sub-Saharan Africa's largest producer of granular urea, a key input for agricultural fertiliser production.
The White & Case team which advised on the transaction was led by partners Deji Adegoke (London) and Gareth Hodder (Dubai) and included partner Martin Menski (Washington, DC), local partners Lulama Selele and Matthew Richards (both Johannesburg) and associates Lauren Vallender, Miebi Inokoba (both London), Andrea McKaiser-Walbrugh, Rhulani Matsimbi, Robyn Anderson (all Johannesburg), Margaret Zelenski (Washington, DC) and Ijeoma Oti (New York).
* * *
Original text here: https://www.whitecase.com/news/press-release/white-case-advises-ifc-led-lender-group-us125-billion-financing-indorama-eleme
[Category: BizLaw/Legal]
MAYER BROWN: BRITT MILLER NAMED AMONG TOP 50 WOMEN LEADERS IN LAW OF 2024 BY WOMEN WE ADMIRE
CHICAGO, Illinois, April 17 -- Mayer Brown, a law firm, issued the following news on April 16, 2024:
Mayer Brown partner Britt Miller was again recognized as one of the "Top 50 Women Leaders in Law" by Women We Admire. The publication notes that the 2024 honorees "have made great strides in representation in the American justice system and legal profession."
Britt serves on Mayer Brown's global Management Committee and co-leads the firm's global Antitrust & Competition practice. She focuses on high-stakes antitrust litigation and complex commercial litigation, representing domestic and international
... Show Full Article
CHICAGO, Illinois, April 17 -- Mayer Brown, a law firm, issued the following news on April 16, 2024:
Mayer Brown partner Britt Miller was again recognized as one of the "Top 50 Women Leaders in Law" by Women We Admire. The publication notes that the 2024 honorees "have made great strides in representation in the American justice system and legal profession."
Britt serves on Mayer Brown's global Management Committee and co-leads the firm's global Antitrust & Competition practice. She focuses on high-stakes antitrust litigation and complex commercial litigation, representing domestic and internationalcorporations in price-fixing, market allocation, monopolization, and conspiracy cases, and also counsels clients on general antitrust issues.
For more than two decades, Britt has litigated some of the largest antitrust cases in the US involving a host of different products and industries.
Since joining Mayer Brown in 1998, her antitrust work has involved a variety of products and industries including synthetic rubber, aspartame, resins, household moving services, consumer health products, industrial chemicals, paper products, financial services, fertilizers, and vitamins.
* * *
Original text here: https://www.mayerbrown.com/en/news/2024/04/britt-miller-named-among-the-top-50-women-leaders-in-law-of-2024-by-women-we-admire
[Category: BizLaw/Legal]
K&L GATES FURTHER DEEPENS CORPORATE PRACTICE IN SYDNEY
SYDNEY, Australia, April 17 -- K&L Gates, a law firm, issued the following news release:
Global law firm K&L Gates has further bolstered its Corporate practice with the appointment of Divesh Patel as a partner. Patel joins K&L Gates in Sydney from Johnson Winter Slattery, where he was a partner in the firm's private equity and M&A practice groups.
Patel is dual qualified in Australia and South Africa and regularly advises leading domestic and international clients, including private equity sponsors, across a range of sectors including transport and logistics, manufacturing, retail, FMCG, financial
... Show Full Article
SYDNEY, Australia, April 17 -- K&L Gates, a law firm, issued the following news release:
Global law firm K&L Gates has further bolstered its Corporate practice with the appointment of Divesh Patel as a partner. Patel joins K&L Gates in Sydney from Johnson Winter Slattery, where he was a partner in the firm's private equity and M&A practice groups.
Patel is dual qualified in Australia and South Africa and regularly advises leading domestic and international clients, including private equity sponsors, across a range of sectors including transport and logistics, manufacturing, retail, FMCG, financialservices, infrastructure, aviation, media, technology and telecommunications.
His extensive transactional experience and cross-sector insights gained from advising on private equity, joint ventures, and other complex commercial transactions, as well as distressed sale transactions and restructurings, will add depth and breadth to our global corporate offerings and foreign investment-related capabilities.
K&L Gates' Regional Managing Partner, Australia, Jason Opperman said: "We are delighted to welcome Divesh to the firm; his appointment further strengthens our corporate and commercial capabilities in Australia. It also represents our continued commitment to deliberately and strategically growing and investing in areas that are in high demand by our clients and the wider market."
Corporate practice area leader Chris Nikou commented: "We are thrilled to have Divesh join the team, he has an outstanding reputation for his skill in corporate M&A and private equity transactions, which aligns perfectly with our global platform."
Patel is the third partner to join the firm's Corporate practice in Australia in recent months. His arrival follows the appointments of Corporate partners Khilen Devani and Carl Hinze based in Brisbane in March 2024, Real estate partner Justin O'Callaghan, Brisbane and Finance partner Claudine Salameh in Sydney with the number of Australian partners rising to 77.
K&L Gates' Corporate practice is one of the most substantial in the legal industry, with more than 500 lawyers in offices on five continents assisting clients in the structuring, financing, and completion of domestic, international, and cross-border transactions. The group serves as counsel to a broad array of Global 500, Fortune 100, FTSE 100 corporations, privately held and venture-backed companies, partnerships, private equity firms, other investment funds, management groups, and entrepreneurs.
K&L Gates is a fully integrated global law firm with lawyers located across five continents. The firm represents leading multinational corporations, growth and middle-market companies, capital markets participants and entrepreneurs in every major industry group as well as public sector entities, educational institutions, philanthropic organizations and individuals.
* * *
Original text here: https://www.klgates.com/KL-Gates-Further-Deepens-Corporate-Practice-in-Sydney-4-16-2024
[Category: BizLaw/Legal]
GSK's 5-in-1 Meningococcal ABCWY Vaccine Candidate Accepted for Regulatory Review by US FDA
LONDON, England, April 17 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on April 16, 2024:
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate. The Prescription Drug User Fee Act (PDUFA) action date for a regulatory decision by the US FDA on this application is 14 February 2025.
GSK's 5-in-1 MenABCWY vaccine candidate combines the antigenic components of its two well-established meningococcal vaccines
... Show Full Article
LONDON, England, April 17 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on April 16, 2024:
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate. The Prescription Drug User Fee Act (PDUFA) action date for a regulatory decision by the US FDA on this application is 14 February 2025.
GSK's 5-in-1 MenABCWY vaccine candidate combines the antigenic components of its two well-established meningococcal vaccineswith demonstrated efficacy and safety profiles, Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). The MenABCWY combination will target the five groups of the bacteria Neisseria meningitidis (Men A, B, C, W and Y) that cause most invasive meningococcal disease (IMD) cases globally.1
Combining the protection offered by these vaccines into fewer shots aims to reduce the number of injections, simplifying immunisation. This can help increase series completion and vaccination coverage and help reduce the overall burden of IMD, with unvaccinated adolescents being at particular risk of infection and potential outbreaks.2,3,4
IMD is an unpredictable but serious illness that can cause life-threatening complications.5 Despite treatment, among those who contract IMD one in six will die, sometimes in as little as 24 hours.6,7 One in five survivors may suffer long-term consequences such as brain damage, amputations, hearing loss and nervous system problems.8 Although anyone can get IMD, those who are in their late teens and early adulthood are amongst the groups at higher risk of contracting it.9,10
In the US, while meningococcal vaccine recommendations for all five serogroups have been in place since 2015, annual immunisation rates for IMD have remained low overall, due in part to a complex schedule.11 MenB is the most common group of IMD-causing bacteria in US adolescents and young adults, accounting for more than half of the IMD cases among this age group in the US from 2017-2021.12 For protection against MenB, which is subject to the shared clinical decision-making recommendation of the CDC, just under 12% of US adolescents have had the two required doses.10
In the phase III trial (NCT04502693), all primary endpoints were achieved for the MenABCWY vaccine candidate, including immunological non-inferiority to one dose of GSK's Meningococcal Groups A,C,Y and W Vaccine, and non-inferior immune responses against 110 diverse MenB invasive strains (representing 95% of MenB strains circulating in the US) as compared to two doses of GSK's Meningococcal Group B Vaccine. The vaccine was well tolerated with a safety profile consistent with both vaccines.13
* * *
About the MenABCWY phase III trial
The trial conducted by GSK was a phase III randomised, controlled, observer-blind, multi-country trial to evaluate the safety, tolerability and immunogenicity of GSK's MenABCWY vaccine candidate. The trial started in August 2020, and approximately 3,650 participants aged 10-25 were enrolled in the US, Canada, Czech Republic, Estonia, Finland, Turkey and Australia.
The objective of the trial was to assess the safety profile of the MenABCWY vaccine candidate, to assess the immunological vaccine effectiveness against a panel of 110 MenB strains and to demonstrate non-inferiority of the immune responses of the trial's participants who received two doses of the MenABCWY vaccine candidate six months apart to the responses of those in the control groups who received GSK's licensed vaccines: two doses of Meningococcal Group B Vaccine and one dose of Meningococcal Groups A,C,Y and W Vaccine.
* * *
About Bexsero
Bexsero is currently licensed or has received regulatory approval in 55 countries, including the US and EU, and is used in 16 national immunisation programmes worldwide for the prevention of IMD caused by Neisseria meningitidis serogroup B. In the US, it is licensed under the Accelerated Approval pathway for active immunisation to prevent IMD caused by Neisseria meningitidis serogroup B in individuals from 10 through 25 years. As required under the FDA's Accelerated Approval regulations, GSK has completed a confirmatory trial of this vaccine and submitted a supplemental Biologics License Application (sBLA) to convert the accelerated approval to full approval. The US Prescribing Information is available here.14
* * *
About Menveo
Menveo has received regulatory approval in over 60 countries, including the US, with more than 72 million doses distributed worldwide since 2010. It offers extensive evidence of immunogenicity with a well-characterised safety profile. In the US, this vaccine has received regulatory approval for active immunisation to prevent IMD caused by Neisseria meningitidis serogroups A, C, Y, and W in individuals from 2 months through 55 years of age. The US Prescribing Information is available here.15
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in the company's Annual Report on Form 20-F for 2023.
* * *
References
1. CDC. Meningococcal Disease Causes and How It Spreads. Available at: https://www.cdc.gov/meningococcal/about/causes-transmission.html. Accessed April 2024.
2. Bekkat-Berkani R, Fragapane E, Preiss S, Rappuoli R et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB, Journal of Infection Vol 85, Issue 5, p481-491, published November 2022.
3. Huang L, Snedecor S et al. Potential public health impact of a Neisseria meningitidis A, B, C, W, and Y pentavalent vaccine in the United States, Postgraduate Medicine, 134(4):341-348 published May 2022.
4. CDC. University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018 - Volume 25, Number 3--March 2019 - Emerging Infectious Diseases journal - CDC. Available at: https://wwwnc.cdc.gov/eid/article/25/3/18-1574_article. Accessed April 2024.
5. CDC. Bacterial Meningitis, Available at: http://www.cdc.gov/meningitis/bacterial.html. Accessed April 2024.
6. World Health Organisation. Meningitis fact sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/meningitis. Accessed April 2024.
7. Thompson MJ et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006. 367, 397-403.
8. CDC. Meningococcal disease: clinical information. Available at: https://www.cdc.gov/meningococcal/clinical-info.html. Accessed April 2024.
9. McNamara LA, Blain A. Meningococcal Disease Roush SW, Baldy LM, Hall MAK, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention. Reviewed January 5, 2022. Accessed April 2024.
10. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13-17 years -- National Immunization Survey-Teen, United States, 2022. MMWR 2023; 72(34): 912-919.
11. Schillie S. Revising the Adolescent Meningococcal Vaccine Schedule: Term of Reference and Considerations. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/02-Meningitis-Schillie-508.pdf. Accessed April 2024.
12. CDC. Enhanced Meningococcal Disease Surveillance Reports, 2017-2021. Available at: http://www.cdc.gov/meningococcal/surveillance/index.html#enhanced-reports. Accessed April 2024.
13. NIH. Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults, ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT04502693. Accessed April 2024.
14. GSK. Highlights Of Prescribing Information Bexsero. Available at: gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF. Accessed April 2024.
15. GSK. Highlights Of Prescribing Information Menveo. Available at: gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF. Accessed April 2024.
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/gsk-s-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda/
[Category: BizPharmaceuticals]
Evergy to Conduct 2024 Shareholders Meeting Online
KANSAS CITY, Missouri, April 17 -- Energy Inc., a company that says it focuses on producing, transmitting and delivering energy for the benefit of stakeholders, issued the following news release on April 16, 2024:
On Tuesday, May 7, 2024, Evergy, Inc. (NASDAQ: EVRG) will conduct its 2024 Annual Meeting of Shareholders.
The virtual meeting will begin at 11:00 a.m. Eastern (10:00 a.m. Central) and can be accessed at http://www.virtualshareholdermeeting.com/EVRG2024.
To participate, all shareholders must enter the control number found on their proxy cards or voting instruction forms.
At the meeting,
... Show Full Article
KANSAS CITY, Missouri, April 17 -- Energy Inc., a company that says it focuses on producing, transmitting and delivering energy for the benefit of stakeholders, issued the following news release on April 16, 2024:
On Tuesday, May 7, 2024, Evergy, Inc. (NASDAQ: EVRG) will conduct its 2024 Annual Meeting of Shareholders.
The virtual meeting will begin at 11:00 a.m. Eastern (10:00 a.m. Central) and can be accessed at http://www.virtualshareholdermeeting.com/EVRG2024.
To participate, all shareholders must enter the control number found on their proxy cards or voting instruction forms.
At the meeting,shareholders will vote to elect 10 members of the Board of Directors and other business matters set forth in the notice of the meeting.
Event: Evergy 2024 Annual Meeting of Shareholders
Date: May 7, 2024
Time: 11 a.m. Eastern (10 a.m. Central)
Access: http://www.virtualshareholdermeeting.com/EVRG2024
* * *
About Evergy, Inc.
Evergy, Inc. (NASDAQ: EVRG) serves 1.7 million customers in Kansas and Missouri. Evergy's mission is to empower a better future. Our focus remains on producing, transmitting and delivering reliable, affordable, and sustainable energy for the benefit of our stakeholders. Today, about half of Evergy's power comes from carbon-free sources, creating more reliable energy with less impact to the environment. We value innovation and adaptability to give our customers better ways to manage their energy use, to create a safe, diverse and inclusive workplace for our employees, and to add value for our investors. Headquartered in Kansas City, our employees are active members of the communities we serve.
* * *
Original text here: https://newsroom.evergy.com/2024-04-16-Evergy-to-conduct-2024-shareholders-meeting-online
[Category: BizEnergy]
Barnes & Thornburg Adds Seasoned Litigator Nicholas Sarokhanian in Minneapolis
MINNEAPOLIS, Minnesota, April 17 -- Barnes and Thornburg, a law firm, issued the following news release on April 16, 2024:
Barnes & Thornburg announced today that experienced litigation and dispute resolution attorney Nicholas A. F. Sarokhanian has joined the firm's Minneapolis office as a partner in its Litigation Department.
Sarokhanian represents businesses in complex, high-stakes disputes with competitors, consumers and regulators, including matters involving multijurisdictional trade secret and non-compete litigation, international asset recovery and clawback litigation, breach of contract
... Show Full Article
MINNEAPOLIS, Minnesota, April 17 -- Barnes and Thornburg, a law firm, issued the following news release on April 16, 2024:
Barnes & Thornburg announced today that experienced litigation and dispute resolution attorney Nicholas A. F. Sarokhanian has joined the firm's Minneapolis office as a partner in its Litigation Department.
Sarokhanian represents businesses in complex, high-stakes disputes with competitors, consumers and regulators, including matters involving multijurisdictional trade secret and non-compete litigation, international asset recovery and clawback litigation, breach of contractand fraud litigation, antitrust and unfair competition litigation, and massive multidistrict litigation and class actions. His clients, ranging from Fortune 500 to startup companies, span a variety of industries, including real estate, healthcare and life sciences, financial services and insurance, and technology and energy.
"Nicholas will be a valuable addition to the firm as businesses in Minnesota and across the U.S. continue to navigate this challenging economic environment," said Connie A. Lahn, managing partner of the firm's Minneapolis office. "His ability to see both the broader strategy and the key details in these complex cases is why clients continue to bring him their thorniest challenges."
Sarokhanian has significant courtroom experience, including jury trial experience in state and federal courts, bench trials in state courts and federal district and bankruptcy courts, and arbitration hearings. At the appellate level, Sarokhanian represents clients in state and federal appellate courts. He has secured favorable published opinions from the U.S. Courts of Appeals for the Fourth and Fifth Circuits that have helped his clients and other businesses with similar challenges.
"Nicholas's deep trial experience and problem-solving acumen are tremendous assets to clients facing disputes that could have critical impacts on their businesses," said D. Randall Brown, chair of the firm's Litigation Department. "Particularly when disputes enter the courtroom, clients want an experienced and trusted litigator like Nicholas representing them. We're excited to have him join the team."
In addition to his legal practice, Sarokhanian is dedicated to supporting his community and providing charitable service. He regularly represents pro bono clients and participates in diversity and inclusion initiatives.
Sarokhanian earned his J.D., cum laude, from Baylor Law School and his B.A., cum laude, from Virginia Polytechnic Institute and State University.
* * *
Original text here: https://btlaw.com/en/insights/news/2024/barnes-thornburg-adds-seasoned-litigator-nicholas-sarokhanian-in-minneapolis
[Category: BizLaw/Legal]
Allianz Life Insurance Co. of North America: New Tool Turns Life Insurance Illustrations Into Full Policy Proposals Instantly
MINNEAPOLIS, Minnesota, April 17 -- Allianz Life Insurance Co. of North America (Allianz Life), a provider of retirement solutions, including fixed and variable annuities and life insurance for individuals, issued the following news release:
Financial professionals who sell life insurance policies for Allianz Life Insurance Company of North America (Allianz Life) can now use a new tool to create customized, interactive policy proposals.
The tool, Illustrations with Impact, powered by the EnsightTM technology platform, helps financial professionals create strong proposals for their clients.
Designed
... Show Full Article
MINNEAPOLIS, Minnesota, April 17 -- Allianz Life Insurance Co. of North America (Allianz Life), a provider of retirement solutions, including fixed and variable annuities and life insurance for individuals, issued the following news release:
Financial professionals who sell life insurance policies for Allianz Life Insurance Company of North America (Allianz Life) can now use a new tool to create customized, interactive policy proposals.
The tool, Illustrations with Impact, powered by the EnsightTM technology platform, helps financial professionals create strong proposals for their clients.
Designedto accompany and expand on a policy proposal, Illustrations with Impact create full presentations that walk clients through all the ways that fixed index universal life insurance (FIUL) can help secure their financial future. With the click of a button, the tool generates personalized client content, including interactive charts, using value drawn from the details of that client's policy illustration. The tool also shows the potential over time for accumulation, loans and withdrawals and even a death benefit.
"It's a powerful way help clients see the positive financial impact in their own life," said Jason Wellmann, head of life distribution for Allianz Life. "But Illustrations with Impact goes beyond the numbers, instantly putting the proposal into a form that's easier for the financial professional to explain - and easier for the client to understand."
The tool pulls from the clients' information to show how a policy can help address concerns like inflation, taxation, market volatility, and longer life expectancies. It also helps clearly explain signature features of an Allianz Life Pro+(R) Advantage Fixed Index Universal Life Policy like Index Lock and Auto Lock that can grow the policy's cash value over time and can help ensure a positive index return in volatile markets.
"Illustrations with Impact helps financial professionals show their clients why they are recommending our life policy," said Wellmann. "It's another way we keep adding more value to our relationship with the people who sell our products."
"Allianz has been at the very forefront of the digital transformation shift over the last several years. We are extremely proud to be helping Allianz enable a better sales experience for Allianz producers and advisors," said Bill Unrue, CEO, Ensight.
* * *
About Ensight(TM)
Ensight(TM) is the leading cloud-based insurance sales acceleration platform for more than 500 life, long-term care (LTC) and annuity distributors, thousands of financial professionals, as well as many of the largest North American insurance carriers. Headquartered in San Diego, California, Ensight helps drive sales growth and productivity, while addressing the entire sales lifecycle experience - from prospect to policyholder, new business to inforce.
Allianz Life and Ensight are not affiliated companies.
* * *
About Allianz Life Insurance Company of North America
Allianz Life Insurance Company of North America, one of the Ethisphere World's Most Ethical Companies(R), has been trusted since 1896 to help millions of Americans prepare for financial uncertainties and retirement with a variety of innovative risk management solutions. In 2023, Allianz Life provided additional value to its policyholders via distributions of more than $13.73 billion. The company is a leading provider of fixed index annuities, registered index-linked annuities, fixed index universal life insurance, and buffered ETFs via our subsidiary Allianz Investment Management, LLC. Allianz Life is part of Allianz SE, a global leader in the financial services industry with approximately 160,000 employees in more than 70 countries. Allianz Life is a proud sponsor of Allianz Field(R) in St. Paul, Minnesota, home of Major League Soccer's Minnesota United.
Guarantees are backed by the financial strength and claims-paying ability of Allianz Life Insurance Company of North America (Allianz).
Products are issued by Allianz Life Insurance Company of North America, 5701 Golden Hills Drive, Minneapolis, MN 55416-1297. 800.950.1962
This content does not apply in the state of New York.
* * *
Original text here: https://www.allianzlife.com/about/newsroom/2024-Press-Releases/New-Tool-Turns-Life-Insurance-Illustrations-into-Full-Policy-Proposals-Instantly
[Category: BizInsurance]
